Search Result

Results for "

BTK kinase

" in MedChemExpress (MCE) Product Catalog:

By Targets:	Btk (69) ADC Cytotoxin (1) Apoptosis (3) BCRP (1) BMX Kinase (2) CDK (1) Cytochrome P450 (2) Dengue virus (1) DNA/RNA Synthesis (1) Drug Metabolite (2) Flavivirus (1) FLT3 (1) Isotope-Labeled Compounds (2) JAK (6) Ligands for Target Protein for PROTAC (2) MNK (1) PI3K (1) Polo-like Kinase (PLK) (1) PROTACs (2) Pyroptosis (1) Src (1) Toll-like Receptor (TLR) (1)
By Research Areas:	Cancer (45) Infection (1) Inflammation/Immunology (30) Metabolic Disease (2) Neurological Disease (3)

Inhibitors & Agonists

Screening Libraries

Peptides

Recombinant Proteins

Isotope-Labeled Compounds

Antibodies

Targets Recommended: Btk

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-139660

PROTAC PTK6 ligand-1	Ligands for Target Protein for PROTAC	Cancer
PROTAC PTK6 ligand-1 is an intermediate for BTK kinase inhibitor preparation . PROTAC PTK6 ligand-1 can be used in the synthesis of ARD-61 (HY-139659) .

HY-101474S

Zanubrutinib-d5 BGB-3111 d₅	Btk	Cancer
Zanubrutinib-d₅ is deuterium labeled Zanubrutinib. Zanubrutinib is a selective Bruton tyrosine kinase (Btk) inhibitor[1].

HY-144288

BLK-IN-2	Btk	Cancer
BLK-IN-2 (compound 25) is a potent and selective irreversible inhibitor of *B-Lymphoid tyrosine kinase* (BLK), with an IC₅₀ of 5.9 nM. BLK-IN-2 also inhibits BTK (IC₅₀**=202.0 nM). BLK-IN-2 shows potent antiproliferative activities against several lymphoma cells .

HY-135334

ACP-5862 1 Publications Verification	Drug Metabolite Btk Cytochrome P450	Cancer
ACP-5862 is a major active, circulating, pyrrolidine ring-opened metabolite of Acalabrutinib with an IC₅₀ of 5.0 nM for Bruton tyrosine kinase (BTK). ACP‐5862 is a weak time‐dependent inactivator of CYP3A4 and CYP2C8. Acalabrutinib is an orally active, irreversible, and highly selective BTK inhibitor, with an IC₅₀ of 3 nM and EC₅₀ of 8 nM .

HY-109192

Tolebrutinib 4 Publications Verification SAR442168; PRN2246	Btk	Neurological Disease
Tolebrutinib (SAR442168) is a potent, selective, orally active and brain-penetrant inhibitor of Bruton tyrosine kinase (BTK), with IC₅₀s of 0.4 and 0.7 nM in Ramos B cells and in HMC microglia cells, respectively. Tolebrutinib exhibits efficacy in central nervous system immunity. Tolebrutinib can be used for the research of multiple sclerosis (MS) .

HY-130665

TL12-186 1 Publications Verification	PROTACs CDK	Cancer
TL12-186 is a Cereblon-dependent multi-kinase PROTAC degrader. Multi-kinases include CDK, *BTK, FLT3, Aurora kinases, TEC, ULK, ITK, et al. TL12-186 inhibits CDK2/cyclin A* (IC₅₀=73 nM) and CDK9/cyclin T1 (IC₅₀=55 nM) .

HY-162081

BTK-IN-32	Btk	Cancer
BTK-IN-32 (compound C2) is a potent inhibitor of *BTK. BTK-IN-32 activates full-length BTK* and smaller multidomain BTK fragments instead of the isolated kinase domain .

HY-P10609

Btk substrate peptide	Btk	Others
Btk substrate peptide is a peptide substrate corresponding to residues 217-229 of human Bruton’s tyrosine kinase (Btk), of which the tyrosine at residue 223 is the major autophosphorylation site of *Btk. Btk* substrate peptide is used as a substrate in in vitro kinase assays to evaluate the activity of *Btk* or other tyrosine kinases .

HY-150752

BTK-IN-15	Btk Pyroptosis	Cancer
BTK-IN-15 (compound 42) is a potent Bruton's tyrosine kinase (BTK) inhibitor with high oral absorption. BTK-IN-15 inhibits *BTK* with an IC₅₀ value of 0.7 nM. BTK-IN-15 displays excellent kinase selectivity, antitumor activity, and induces apoptosis .

HY-160167

BTK-IN-30	Btk	Inflammation/Immunology
BTK-IN-30 (compound cpd15) is an inhibitor of Bruton's Tyrosine Kinase (BTK) and mutant BTK with IC₅₀ values of 6.72 and 6.11nM respectively .

HY-123117

VA5	Btk	Inflammation/Immunology
VA5 is a BTK kinaseinhibitor. VA5 has the potential to be used to study diseases associated with BTK kinase activity.

HY-130255

BTK inhibitor 13	Btk	Inflammation/Immunology
BTK inhibitor 13 (compound 8) is a potent and selective Bruton's tyrosine kinase (BTK) inhibitor with an IC₅₀ of 1.2 nM .

HY-153951S

BTK-IN-26	Btk	Inflammation/Immunology Cancer
BTK-IN-26 (compound 18) is a potent inhibitor of Bruton's tyrosine kinase (BTK) and its C481 mutant, with IC₅₀ values of 0.7 and 0.8 nM for *BTK* and BTK C481S, respectively. BTK-IN-26 can be used for cancer and autoimmune diseases research .

HY-125997

BTK inhibitor 10	Btk	Inflammation/Immunology
BTK inhibitor 10 is a potent and orally active Bruton kinase (BTK) inhibitor, extracted from patent WO2018145525, example 33. BTK inhibitor 10 has a potential for rheumatoid arthritis treatment .

HY-101766

Btk inhibitor 2 BGB-3111 analog	Btk	Inflammation/Immunology
Btk inhibitor 2 (BGB-3111 analog) is a Bruton's tyrosine kinase (BTK) inhibitor extracted from patent US 20170224688 A1.

HY-131328

Pirtobrutinib 2 Publications Verification LOXO-305	Btk	Cancer
Pirtobrutinib (LOXO-305), a highly selective and non-covalent next generation *BTK* inhibitor, inhibits diverse BTK C481 substitution mutations. Pirtobrutinib causes regression of BTK-dependent lymphoma tumors in mouse xenograft models. Pirtobrutinib is also more than 300-fold selective for BTK versus 370 other kinases tested and shows no significant inhibition of non-kinase off-targets at 1 μM .

HY-148585

BTK-IN-22	Btk	Cancer
BTK-IN-22 is a *BTK* inhibitor (IC₅₀: 0.9 nM). BTK-IN-22 also inhibits BLX and BMX with IC₅₀s of 1.4 and 1.2 nM respectively. BTK-IN-22 shows improved kinase selectivity compared to Ibrutinib (HY-10997)

HY-148594

BTK-IN-23	Btk	Cancer
BTK-IN-23 is a *BTK* inhibitor (IC₅₀: 12.8 nM). BTK-IN-23 also inhibits BLX and BMX with IC₅₀s of 35.6 and 5.7 nM respectively. BTK-IN-23 shows improved kinase selectivity compared to Ibrutinib (HY-10997) .

HY-148832

BTK-IN-20	Btk	Inflammation/Immunology Cancer
BTK-IN-20 (compound 283) is a *BTK* tyrosine kinase inhibitor and a 1H-pyrazolo[3,4-d]pyrimidine derivative. BTK-IN-20 can be used for the research of cancer and inflammation .

HY-163295

BTK degrader-1	ADC Cytotoxin Btk	Cancer
BTK degrader-1 (compound 1) is a Bruton’s tyrosine kinase (BTK) bifunctional degrader that can be conjugated with CD79b. BTK degrader-1 (compound 1) has anti-tumor effect .

HY-18016

CGI 560	Btk	Inflammation/Immunology
CGI 560 is an inhibitor for Bruton's tyrosine kinase (BTK) with an IC₅₀ of 400 nM.

HY-151211

BTK-IN-16	Btk	Inflammation/Immunology Cancer
BTK-IN-16 is a dual inhibitor of BTK wild type and C481S mutant of Bruton’s tyrosine kinase (BTK) with IC₅₀s of 5.1 and 4.1 μM. BTK-IN-16 can be used for the research of autoimmune diseases and chronic lymphocytic leukemia .

HY-142932

BTK-IN-6	Btk	Neurological Disease Inflammation/Immunology Cancer
BTK-IN-6 is a potent inhibitor of Bruton's Tyrosine Kinase (BTK). BTK is a member of the Tec family of tyrosine kinases and plays an important role in the regulation of early B-cell development and mature B-cell activation and survival. BTK-IN-6 has the potential for the research of immune disorders, cancer, cardiovascular diseases, viral infections, inflammation, metabolism/endocrine function disorders, and neurological disorders (extracted from patent WO2021136219A1, compound 8) .

HY-143717

JAK3/BTK-IN-2	JAK Btk	Inflammation/Immunology
JAK3/BTK-IN-2 is a potent inhibitor of *JAK3/BTK*. BTK and JAK3 are two important targets for autoimmune diseases. Simultaneous inhibition of the BTK/JAK3 signalling pathway exhibits synergistic effects. JAK3/BTK-IN-2 has the potential for the research of JAK3 kinase and/or BTK-related diseases (extracted from patent WO2021147952A1, compound 004)

HY-143720

JAK3/BTK-IN-5	JAK Btk	Inflammation/Immunology
JAK3/BTK-IN-5 is a potent inhibitor of *JAK3/BTK*. BTK and JAK3 are two important targets for autoimmune diseases. Simultaneous inhibition of the BTK/JAK3 signalling pathway exhibits synergistic effects. JAK3/BTK-IN-5 has the potential for the research of JAK3 kinase and/or BTK-related diseases (extracted from patent WO2021147953A1, example 35)

HY-143716

JAK3/BTK-IN-1	JAK Btk	Inflammation/Immunology
JAK3/BTK-IN-1 is a potent inhibitor of *JAK3/BTK*. BTK and JAK3 are two important targets for autoimmune diseases. Simultaneous inhibition of the BTK/JAK3 signalling pathway exhibits synergistic effects. JAK3/BTK-IN-1 has the potential for the research of JAK3 kinase and/or BTK-related diseases (extracted from patent WO2021147952A1, compound 002) .

HY-143718

JAK3/BTK-IN-3	JAK Btk	Inflammation/Immunology
JAK3/BTK-IN-3 is a potent inhibitor of *JAK3/BTK*. BTK and JAK3 are two important targets for autoimmune diseases. Simultaneous inhibition of the BTK/JAK3 signalling pathway exhibits synergistic effects. JAK3/BTK-IN-3 has the potential for the research of JAK3 kinase and/or BTK-related diseases (extracted from patent WO2021147952A1, compound 009)

HY-143719

JAK3/BTK-IN-4	JAK Btk	Inflammation/Immunology
JAK3/BTK-IN-4 is a potent inhibitor of *JAK3/BTK*. BTK and JAK3 are two important targets for autoimmune diseases. Simultaneous inhibition of the BTK/JAK3 signalling pathway exhibits synergistic effects. JAK3/BTK-IN-4 has the potential for the research of JAK3 kinase and/or BTK-related diseases (extracted from patent WO2021147953A1, compound 003)

HY-10644

Lck inhibitor 2	Src	Inflammation/Immunology
Lck inhibitor 2 is a multi-target tyrosine kinase inhibitor with IC50s of 13nM, 9nM, 3nM, 26nM and 2nM for Lck, Btk, Lyn, Btk and Txk respectively.

HY-112215

Nemtabrutinib 2 Publications Verification ARQ-531; MK-1026	Btk	Inflammation/Immunology Cancer
ARQ 531 (MK-1026) is a reversible non-covalent and orally active inhibitor of Bruton’s Tyrosine Kinase (BTK), with IC₅₀s of 0.85 nM and 0.39 nM for WT-BTK and C481S-BTK, respectively.

HY-156604

Cinsebrutinib	Btk	Cancer
Cinsebrutinib is a Bruton's tyrosine kinase inhibitor, extracted from patent WO2021207549 (compound 5-6). Cinsebrutinib has the potential for cancer study.

HY-100338

CNX-500	Btk	Cancer
CNX-500 is a probe consisting of a covalent *Btk* inhibitor (CC-292) chemically linked to biotin. CNX-500 retains inhibitory activity against *Btk* (IC₅₀ of 0.5 nM) and the ability to form a covalent bond with *Btk. CNX-500 has low inhibitory effects on kinase* epidermal growth factor receptor, and upstream Src-family kinases including Syk and Lyn .

HY-150885

BTK ligand 1	Ligands for Target Protein for PROTAC Btk	Cancer
BTK ligand 1 (compound 1) is a ligand targeting Bruton’s tyrosine kinase (Btk). BTK ligand 1 can combine with E3 ligase ligand (Ligand for E3 Ligase) through PROTAC Linker to form PROTAC. PROTACs targeting *Btk* can be used in the study of chronic lymphocytic leukemia (CLL) and other BK cell malignancies .

HY-100335

PCI-33380 1 Publications Verification	Btk	Others
PCI-33380 is an irreversible and selective Bruton's Tyrosine Kinase *(BTK)* inhibitor (fluorescent probe).

HY-101793

BMS-935177	Btk	Inflammation/Immunology
BMS-935177 is a potent and selective reversible inhibitor of Bruton’s tyrosine kinase (Btk) with an IC₅₀ of 3 nM.

HY-109143

Elsubrutinib ABBV-105	Btk	Inflammation/Immunology
Elsubrutinib (ABBV-105) is an orally active, potent, selective and irreversible Bruton's tyrosine kinase (BTK) inhibitor。The IC₅₀ of Elsubrutinib for BTK catalytic domain is 0.18 μM. Elsubrutinib can be used for the research of inflammatory disease .

HY-101856

BMS-986142	Btk	Inflammation/Immunology
BMS-986142 is a potent and highly selective reversible inhibitor of Bruton's tyrosine kinase (BTK) with an IC₅₀ of 0.5 nM.

HY-156743

DCAF1 binder 2	Others	Others
DCAF1 binder 2, a ligands for E3 Ligase, involves in BRD9, kinase and selective BTK degration.

HY-129390

Orelabrutinib ICP-022	Btk	Cancer
Orelabrutinib (ICP-022) is a potent, orally active, and irreversible Bruton's tyrosine kinase (BTK) inhibitor with potential antineoplastic activity. Orelabrutinib prevents both the activation of the B-cell antigen receptor (BCR) signaling pathway and BTK-mediated activation of downstream survival pathways, inhibiting the growth of malignant B-cells that overexpress BTK .

HY-163565

BIIB129	Btk	Neurological Disease
BIIB129 is a covalent, selective, small molecule inhibitor of Bruton's tyrosine kinase (BTK) capable of penetrating the blood-brain barrier. BIIB129 inhibits the activity of *BTK* by covalently binding to Cys481 in *BTK*, thereby affecting the function of B cells and myeloid cells. BIIB129 can be used in multiple sclerosis (MS) research .

HY-128757

Remibrutinib 3 Publications Verification LOU064	Btk	Inflammation/Immunology
Remibrutinib, is a potent and orally active bruton tyrosine kinase (BTK) inhibitor with an IC₅₀ value of 1 nM. Remibrutinib inhibits BTK activity with an IC₅₀ value of 0.023 μM in blood . Remibrutinib has the potential for Chronic urticaria (CU) treatment .

HY-101474B

(R)-Zanubrutinib (R)-BGB-3111	Btk	Others
(R)-Zanubrutinib is the R enantiomer of Zanubrutinib (HY-101474A). (R)-Zanubrutinib inhibits Bruton's tyrosine kinase (Btk) with an IC₅₀ of 11 nM.

HY-124645

QL-X-138	Flavivirus Dengue virus Btk MNK	Infection Cancer
QL-X-138 is a potent and selective **BTK/MNK dual kinase** inhibitor, exhibits covalent binding to BTK and non-covalent binding to MNK. QL-X-138 shows IC₅₀s of 9.4 nM, 107.4 nM and 26 nM for BTK, MNK1 and MNK2 kinases respectively. QL-X-138 also shows anti-dengue virus 2 activity, with an IC₅₀ of 3.5 μM. QL-X-138 can be used for the research of B-cell malignancies .

HY-160141

BTK-IN-29	Btk	Cancer
BTK-IN-29 (compound 14) is an inhibitor of Btk .

HY-131342

BIIB068	Btk	Inflammation/Immunology
BIIB068 is a potent, selective, reversible and orally active *BTK* inhibitor with an IC₅₀ of 1 nM and a K_d of 0.3 nM. BIIB068 shows more >400-fold selective for *BTK* than other kinases. BIIB068 has the potential for autoimmune diseases research .

HY-101474A

Zanubrutinib Maximum Cited Publications 12 Publications Verification BGB-3111	Btk	Cancer
Zanubrutinib (BGB-3111) is a selective and orally active Bruton tyrosine kinase (Btk) inhibitor (IC₅₀: 0.3 nM) .

HY-112166

Rilzabrutinib PRN1008	Btk	Metabolic Disease Cancer
Rilzabrutinib (PRN1008) is a reversible covalent, selective and oral active inhibitor of Bruton’s Tyrosine Kinase *(BTK), with an IC₅₀* of 1.3 nM.

HY-101474

(±)-Zanubrutinib 3 Publications Verification (±)-BGB-3111	Btk	Cancer
(±)-Zanubrutinib ((±)-BGB-3111) is the racemate of Zanubrutinib (HY-101474A). (±)-Zanubrutinib inhibits Bruton's tyrosine kinase (Btk) with an IC₅₀ of 0.63 nM .

HY-164002

PF-303	Btk	Others
PF-303 is a potent, oral inhibitor of Bruton's tyrosine kinase (BTK) (IC₅₀=0.64 nM). The melamine portion of PF-303 forms a covalent bond with *BTK's* Cys481, which is reversible and exhibits a high selectivity compared to irreversible covalent *BTK* inhibitors. PF-303 can be used to model and study the effects of *BTK* inhibition on the mature immune system, including effects on B-cell subsets, antibody responses, and T-cell-mediated activation .

HY-W062695

(R)-Acalabrutinib (R)-ACP-196	Btk	Cancer
(R)-Acalabrutinib ((R)-ACP-196) is the enantiomer of Acalabrutinib (HY-17600). (R)-Acalabrutinib is an inhibitor for Bruton’s tyrosine kinase (BTK) .

Cat. No.	Product Name

HY-L009

Kinase Inhibitor Library

2,689 compounds

Kinase is an enzyme that adds phosphate groups to other molecules. This process is known as phosphorylation. Protein phosphorylation is a key aspect in the regulation of a large number of cellular processes including cellular division, metabolism, signal transduction, and so on. There are over 500 kinases encoded by the human genome and it has been estimated that kinases regulate approximately 50% of cellular functions. Kinases are a large group of drug targets in drug discovery. Kinase inhibitors are an important class of drugs that block certain enzymes involved in diseases such as cancer and inflammatory disorders.

Kinase inhibitor library designed by MCE contains 2,689 kinase inhibitors and regulators mainly targeting protein kinases (VEGFR, EGFR, BTK, CDK, Akt, etc.), lipid kinases (PI3K, PI4K, SK, etc.) and carbohydrate kinases (Hexokinase), and is a useful tool for kinase drug discovery and related research.

HY-L016

Protein Tyrosine Kinase Compound Library

1,064 compounds

Protein tyrosine kinases (PTKs) are key signaling molecules and important drug targets. Two classes of PTKs are present in cells: the transmembrane receptor PTKs (RTKs) and the nonreceptor PTKs. The RTK family includes the receptors for insulin and for many growth factors, such as EGFR, FGFR, PDGFR, VEGFR, and NGFR. RTKs are transmembrane glycoproteins that are activated by the binding of their ligands, and they transduce the extracellular signal to the cytoplasm by phosphorylating tyrosine residues on the receptors themselves (autophosphorylation) and on downstream signaling proteins. Their principal functions of PTKs involve the regulation of multicellular aspects of the organism. Cell to cell signals concerning growth, differentiation, adhesion, motility, and death are frequently transmitted through tyrosine kinases. In humans, tyrosine kinases have been demonstrated to play significant roles in the development of many disease states, including diabetes and cancers.

MCE designs a unique collection of 1,064 compounds that act as a useful tool for PTKs-related drug screening and disease research.

HY-L156

Autoimmune Disease Compound Library

500 compounds

Autoimmune disease is a pathological disease characterized by inflammatory disorders targeting autoantigens. The routine treatment of autoimmune diseases suppresses general immune function to regulate uncontrolled inflammation. The current targeted immunotherapy suppresses the main pro-inflammatory signaling pathways by blocking inflammatory cytokines, cell surface molecules, and intracellular kinases. As key participants in innate immunity, macrophages and dendritic cells (DCs) are crucial for Ag presentation and pro-inflammatory cytokine production, such as TNF and IL-1 β、 IL-6, IL-23, B cell activating factor (BAFF), and the proliferation-inducing ligand (APRIL, also known as TNFSF13A).

MCE designs a unique collection of 500 autoimmune disease-related compounds, covering multiple targets and subtypes, such as TNF Receptor, IFNAR, JAK, Btk, TLR, IL-6, IL-17, IL-23, etc. It is a useful tool for screening autoimmune disease drugs.

Cat. No.	Product Name	Target	Research Area

HY-P5438

Srctide	Peptides	Others
Srctide is a biological active peptide. (This is a peptide substrate for many protein kinases, such as Blk, BTK, cKit, EPHA1, EPHB2, EPHB3, ERBB4, FAK, Flt3, IGF-1R, ITK, Lck, MET, MUSK, Ret, Src, TIE2, TrkB, VEGF-R1 (Flt-1) and VEGF-R2 (KDR).)

HY-P10609

Btk substrate peptide	Btk	Others
Btk substrate peptide is a peptide substrate corresponding to residues 217-229 of human Bruton’s tyrosine kinase (Btk), of which the tyrosine at residue 223 is the major autophosphorylation site of *Btk. Btk* substrate peptide is used as a substrate in in vitro kinase assays to evaluate the activity of *Btk* or other tyrosine kinases .

Species:	Human (3)
Tag:	His (3) Avi (1)
Source:	Sf9 insect cells (2) P. pastoris (1)

Cat. No.	Compare	Product Name	Species	Source

HY-P702730

	BTK Protein, Human (Biotinylated, sf9, His, Avi) BTK; Bruton agammaglobulinemia tyrosine kinase; tyrosine-protein kinase BTK	Human	Sf9 insect cells
	The BTK protein is a key non-receptor tyrosine kinase that is essential for B lymphocyte development and signaling. After BCR activation, BTK initiates a cascade reaction, phosphorylates PLCG2 and activates downstream pathways, affecting calcium mobilization and PKC activation. BTK Protein, Human (Biotinylated, sf9, His, Avi) is the recombinant human-derived BTK, expressed by Sf9 insect cells , with His, Avi labeled tag. ,

HY-P72048

	BTK Protein, Human (Sf9, His) Agammaglobulinaemia tyrosine kinase; AGMX 1; AGMX1; AT; ATK; B cell progenitor kinase; B-cell progenitor kinase; BPK; Bruton agammaglobulinemia tyrosine kinase; Bruton tyrosine kinase; Bruton Tyrosine kinase; BTK; BTK_HUMAN; dominant-negative kinase-deficient Brutons tyrosine kinase; IMD 1; IMD1; MGC126261; MGC126262; OTTHUMP00000063593; PSCTK 1; PSCTK1; truncated Bruton agammaglobulinemia tyrosine kinase; Tyrosine protein kinase BTK; Tyrosine-protein kinase BTK; tyrosine-protein kinase BTK isoform lacking exon 14; XLA	Human	Sf9 insect cells
	The BTK protein is a key non-receptor tyrosine kinase that is essential for B lymphocyte development and signaling. After BCR activation, BTK initiates a cascade reaction, phosphorylates PLCG2 and activates downstream pathways, affecting calcium mobilization and PKC activation. BTK Protein, Human (Sf9, His) is the recombinant human-derived BTK protein, expressed by Sf9 insect cells , with N-10*His labeled tag.

HY-P700598

	BTK Protein, Human (P. pastoris, His) Agammaglobulinemia tyrosine kinase ; ATKB-cell progenitor kinase ; BPKBruton tyrosine kinase	Human	P. pastoris
	BTK Protein, a key non-receptor tyrosine kinase, is essential for B lymphocyte development and signaling. Upon BCR activation, BTK initiates a cascade, phosphorylating PLCG2 and activating downstream pathways, influencing calcium mobilization and PKC activation. In innate and adaptive immunity, particularly TLR pathways, BTK regulates TLR9 activation, induces NF-kappa-B activity, and activates NLRP3 inflammasome assembly. Its multifaceted functions include phosphorylating GTF2I, participating in apoptosis regulation, and serving as a platform for diverse signaling proteins. BTK Protein, Human (P. pastoris, His) is the recombinant human-derived BTK protein, expressed by P. pastoris, with N-6*His labeled tag. The total length of BTK Protein, Human (P. pastoris, His) is 659 a.a., with molecular weight of 78.2 kDa.

Compare Products


Products	In-stock - + Add to Cart
Cat. No.
Species
Source
Tag
Accession
Gene ID
Molecular Weight
Purity
Endotoxin Level
Biological Activity
Appearance
Formulation
Storage & Stability
Shipping
Free Sample	Yes No
Size	* This product has been "discontinued". Optimized version of product available: / In-stock - + Add to Cart Get quote

Cat. No.	Product Name	Chemical Structure

HY-101474S

Zanubrutinib-d5
Zanubrutinib-d₅ is deuterium labeled Zanubrutinib. Zanubrutinib is a selective Bruton tyrosine kinase (Btk) inhibitor[1].

HY-153951S

BTK-IN-26
BTK-IN-26 (compound 18) is a potent inhibitor of Bruton's tyrosine kinase (BTK) and its C481 mutant, with IC₅₀ values of 0.7 and 0.8 nM for *BTK* and BTK C481S, respectively. BTK-IN-26 can be used for cancer and autoimmune diseases research .

HY-101474BS

(R)-Zanubrutinib-d5
(R)-Zanubrutinib-d₅ is deuterium labeled (R)-Zanubrutinib. (R)-Zanubrutinib is the R enantiomer of Zanubrutinib. Zanubrutinib is a selective Bruton tyrosine kinase (BTK) inhibitor.

HY-135334S

ACP-5862-d4

ACP-5862-d₄ is deuterium labeled ACP-5862. ACP-5862 is a major active, circulating, pyrrolidine ring-opened metabolite of Acalabrutinib with an IC50 of 5.0 nM for Bruton tyrosine kinase (BTK). ACP‐5862 is a weak time‐dependent inactivator of CYP3A4 and CYP2C8. Acalabrutinib is an orally active, irreversible, and highly selective BTK inhibitor, with an IC50 of 3 nM and EC50 of 8 nM[1][2].

Cat. No.	Compare	Product Name	Application	Reactivity

HY-P80576

	BTK Antibody (YA816) BTK; AGMX1; ATK; BPK; Tyrosine-protein kinase BTK; Agammaglobulinaemia tyrosine kinase; ATK; B-cell progenitor kinase; BPK; Bruton tyrosine kinase	WB, IP	Human
	BTK Antibody (YA816) is a non-conjugated and Mouse origined monoclonal antibody about 76 kDa, targeting to BTK (5B12). It can be used for WB,IP assays with tag free, in the background of Human.

HY-P80454

	Phospho-BTK(Y223) Antibody BTK(Y223); BTK (phospho Y223); p-BTK (phospho Y223); Agammaglobulinaemia tyrosine kinase; AGMX 1; AGMX1; AT; ATK; B cell progenitor kinase; B-cell progenitor kinase; BPK; Bruton agammaglobulinemia tyrosine kinase; Bruton tyrosine kinase; Bruton’s Tyrosine kinase; BTK; BTK_HUMAN; IMD 1; IMD1; MGC126261; MGC126262; OTTHUMP00000063593; PSCTK 1; PSCTK1; Tyrosine protein kinase BTK; Tyrosine-protein kinase BTK; XLA.	WB, IP	Human
	Phospho-BTK(Y223) Antibody is a non-conjugated and Rabbit origined monoclonal antibody about 76 kDa, targeting to Phospho-BTK(Y223). It can be used for WB, IP assays with tag free, in the background of Human.

HY-P83523

	General Transcription Factor II I Antibody (YA3268) GTF2I; BAP135; WBSCR6; General transcription factor II-I; GTFII-I; TFII-I; Bruton tyrosine kinase-associated protein 135; BAP-135; BTK-associated protein 135; SRF-Phox1-interacting protein; SPIN; Williams-Beuren syndrome chromosomal region	WB, IHC-F, IHC-P, ICC/IF	Human
	General Transcription Factor II I Antibody (YA3268) is a rabbit-derived non-conjugated IgG antibody (Clone NO.: YA3268), targeting General Transcription Factor II I, with a predicted molecular weight of 112 kDa (observed band size: 135/138 kDa). General Transcription Factor II I Antibody (YA3268) can be used for WB, IHC-F, IHC-P, ICC/IF experiment in human background.

Compare Products


Products	In-stock - + Add to Cart
Cat. No.
Host
Reactivity
Application
Dilution Ratio
Molecular Weight
Conjugation
Clonality
Immunogen
Appearance
Isotype
Gene ID
SwissProt ID
Purity
Formulation
Free Sample	Yes No
Size	* This product has been "discontinued". Optimized version of product available: / In-stock - + Add to Cart Get quote

Inquiry Online

Your information is safe with us. * Required Fields.

MCE Japan Authorized Agent ナミキ商事株式会社コスモ・バイオ株式会社
Salutation			Country or Region *
Applicant Name *			Organization Name *
Department *
Email Address *			Product Name *
Cat. No.			Requested quantity *
Phone Number *
Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: